Profile: Centocor, Inc. specializes in the field of biomedicines. Our products are designed to treat cancer and immune-mediated inflammatory disorders, such as rheumatoid arthritis & plaque psoriasis. Our Remicade® blocks the activity of a specific protein identified as an underlying cause of a number of autoimmune diseases, including Crohn's disease, pediatric Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis & plaque psoriasis. Remicade is indicated for the treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. Remicade, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage & improving physical function in patients with moderately to severely active rheumatoid arthritis. It is also indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage & improving physical function in patients with psoriatic arthritis. We also manufacture ReoPro®, indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention, and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours.

The company has revenues of USD 5-10 Million, has ~650 employees and is ISO 9000 certified.